{"id":"sb5","safety":{"commonSideEffects":[{"rate":"10–20","effect":"Injection site reactions"},{"rate":"15–25","effect":"Upper respiratory tract infections"},{"rate":"10–15","effect":"Headache"},{"rate":"2–5","effect":"Serious infections"},{"rate":"<1","effect":"Tuberculosis reactivation"}]},"_chembl":{"chemblId":"CHEMBL5408013","moleculeType":null,"molecularWeight":"563.70"},"_dailymed":{"setId":"002d3e04-7558-4e22-85bb-09e30566bd0b","title":"SB5 (BIIB606) (ADALIMUMAB-BWWD) INJECTION, SOLUTION [CATALENT INDIANA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SB5 is a biosimilar of adalimumab, a TNF-α inhibitor used to treat inflammatory and autoimmune diseases. By neutralizing TNF-α, a key pro-inflammatory cytokine, SB5 suppresses the immune response and reduces inflammation in conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.","oneSentence":"SB5 is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:24:39.748Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT04515186","phase":"PHASE3","title":"Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2021-01-26","conditions":"Cutaneous Leishmaniases","enrollment":184},{"nctId":"NCT06447285","phase":"NA","title":"Early, Objective Detection of Autism.","status":"NOT_YET_RECRUITING","sponsor":"SensoDetect","startDate":"2024-05-29","conditions":"Autism Spectrum Disorder","enrollment":300},{"nctId":"NCT04799236","phase":"PHASE3","title":"Treatment of Mucosal Bolivian Leishmaniasis","status":"RECRUITING","sponsor":"Fundacion Nacional de Dermatologia","startDate":"2021-04-01","conditions":"Mucosal Leishmaniasis","enrollment":120},{"nctId":"NCT05312177","phase":"","title":"Congenital Heart Disease: Impact on Learning and Development in Down Syndrome (CHILD-DS)","status":"COMPLETED","sponsor":"Carelon Research","startDate":"2022-05-01","conditions":"Down Syndrome, Congenital Heart Disease","enrollment":273},{"nctId":"NCT06000514","phase":"PHASE1, PHASE2","title":"Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.","status":"COMPLETED","sponsor":"Hospital Universitário Professor Edgard Santos","startDate":"2019-01-17","conditions":"Cutaneous Leishmaniasis, American","enrollment":20},{"nctId":"NCT05510063","phase":"PHASE4","title":"Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2022-08-04","conditions":"Plaque Psoriasis","enrollment":371},{"nctId":"NCT04514796","phase":"PHASE1","title":"Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2020-08-13","conditions":"Healthy","enrollment":188},{"nctId":"NCT01300975","phase":"PHASE2","title":"Intralesional Antimony for Bolivian Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"Fundacion Nacional de Dermatologia","startDate":"2011-01","conditions":"Leishmaniasis, Cutaneous Leishmaniasis","enrollment":90},{"nctId":"NCT04066673","phase":"","title":"Intelligence Quotient Assessment in Children With Autistic Spectrum Disorders.","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-09","conditions":"Autism Spectrum Disorder","enrollment":40},{"nctId":"NCT02565810","phase":"PHASE2","title":"An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2015-09","conditions":"Rheumatoid Arthritis","enrollment":49},{"nctId":"NCT02326233","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2015-06","conditions":"Healthy","enrollment":190},{"nctId":"NCT00657917","phase":"PHASE2","title":"Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396","status":"TERMINATED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2006-12-20","conditions":"Cutaneous Leishmaniasis","enrollment":1},{"nctId":"NCT02144714","phase":"PHASE1","title":"Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2014-05","conditions":"Healthy","enrollment":189},{"nctId":"NCT02167139","phase":"PHASE3","title":"A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2014-05","conditions":"Rheumatoid Arthritis","enrollment":544},{"nctId":"NCT01381055","phase":"PHASE2, PHASE3","title":"Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"Paulo Roberto Lima Machado","startDate":"2012-03","conditions":"Cutaneous Leishmaniasis","enrollment":164},{"nctId":"NCT00682656","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis","status":"TERMINATED","sponsor":"Ana Rabello","startDate":"2008-06","conditions":"Cutaneous Leishmaniasis","enrollment":48},{"nctId":"NCT00818818","phase":"PHASE4","title":"Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients","status":"COMPLETED","sponsor":"University of Brasilia","startDate":"2008-08","conditions":"Localized Cutaneous Leishmaniasis","enrollment":13},{"nctId":"NCT00973128","phase":"PHASE2","title":"Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"Hospital Universitário Professor Edgard Santos","startDate":"2004-02","conditions":"Cutaneous Leishmaniasis","enrollment":40},{"nctId":"NCT00317980","phase":"PHASE4","title":"Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"University of Brasilia","startDate":"2006-02","conditions":"Cutaneous Leishmaniasis","enrollment":280},{"nctId":"NCT00257530","phase":"PHASE3","title":"Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2005-12","conditions":"Cutaneous Leishmaniasis","enrollment":80},{"nctId":"NCT00111514","phase":"PHASE1","title":"Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis","status":"COMPLETED","sponsor":"Access to Advanced Health Institute (AAHI)","startDate":"2004-07","conditions":"Leishmaniasis, Mucocutaneous","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"SB5","genericName":"SB5","companyName":"Samsung Bioepis Co., Ltd.","companyId":"samsung-bioepis-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"SB5 is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Psoriasis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}